DM
PHAT icon

Deerfield Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Deerfield Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-656,000
Closed -$9.39M – 102
2023
Q2 		$9.39M Buy
+656,000
New +$7.56M 0.2% 72
2022
Q4 		– Sell
-2,414,897
Closed -$26.8M – 116
2022
Q3 		$26.8M Buy
+2,414,897
New +$23M 0.53% 53

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Deerfield Management's PHAT Position: Q3 2023 in Review

Deerfield Management sold out of Phathom Pharmaceuticals (PHAT) in Q3 2023, closing a stake of 656,000 shares — an estimated $9.39M sold.

Deerfield Management first reported a position in PHAT in Q3 2022 and held it in 2 quarters. The position peaked at $26.8M in Q3 2022. 110 funds tracked by Wall St. Rank hold PHAT as of Q3 2023.

  • Deerfield Management reported no remaining Phathom Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Deerfield Management sold 656,000 Phathom Pharmaceuticals shares in Q3 2023, an estimated $9.39M.
  • Deerfield Management first reported a position in Phathom Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Deerfield Management's Phathom Pharmaceuticals position peaked at $26.8M in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2023.

Based on Deerfield Management's 13F filing for Q3 2023, filed 14 Nov 2023.